MedTrace Logo

Retarded Phosphatidylcholine Versus Mesalazin in Remission of Ulcerative Colitis.

NCT00259571 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2013-12-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate if retarded phosphatidylcholine is as effective as mesalazin in preventing an acute episode in ulcerative colitis.

The hypothesis is, that ulcerative colitis is cuased by a defect in the barrier function of the colonic mucus. The background of the study is the finding that the phosphatidylcholine content of the colonic mucus is reduced in patients with ulcerative colitis, in both healthy and inflamed parts of the colon.

Conditions

Interventions

DRUG

retarded release phosphatidylcholine

2g daily, given orally QTD

Sponsors & Collaborators

  • Dietmar Hopp Stiftung

    collaborator OTHER

  • Heidelberg University

    lead OTHER

Principal Investigators

  • Wolfgang Stremmel, Professor · Heidelberg University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2010-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00259571 on ClinicalTrials.gov